Key facts
- gMendel’s last known valuation is $1.6M (Jan 2020).
- It has raised $2.9M; the latest was Seed Round ($1.4M) in Apr 2026.
- Notable investors include CVX Ventures, Eurostars, Innovationsfonden, Metavallon VC, Nordic Asian Venture Alliance — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for gMendel
- ·The full record, as it builds
Funding rounds
No funding rounds for gMendel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About gMendel
Developer of a comprehensive decision support software designed to transform the diagnosis of genetic disorders for better disease management. The company specializes in combining genomics, machine learning, and blockchain to diagnose genetic disorders and provide comprehensive decision support software, which allows for accurate and timely diagnosis of genetics, enabling healthcare professionals with a shorter, safer, and more economical path to accurate diagnosis of genetic disorders and potential treatment.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2020
- Employees
- 12
- Website
- g-mendel.com/
- Ownership
- Privately Held (backing)
gMendel doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in gMendel shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on gMendel in its N-PORT filings yet. We sweep new filings monthly.